(2022). Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus. Diabet Med, e14858. http://doi.org/10.1111/dme.14858.
(2021). Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study. Can J Diabetes. http://doi.org/10.1016/j.jcjd.2021.12.005.
(2015). Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia. http://doi.org/10.1007/s00125-014-3456-9.
(2021). Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2021-002496.
(2021). Risk of hospitalization and death associated with Sodium Glucose Cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs. Diabetes Metab. http://doi.org/10.1016/j.diabet.2021.101305.